Associate Director, Statistical Programming at Corcept Therapeutics

Redwood City, California, United States

Corcept Therapeutics Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, BiotechnologyIndustries

Requirements

  • Experience in statistical programming
  • Knowledge of CDISC standards and regulatory programming
  • Familiarity with SAS programming
  • Understanding of clinical trial data management

Responsibilities

  • Work with data management to review CRO generated case report forms, database specifications, and data transfer specifications
  • Review Statistical Analysis Plan, develop specifications, write and execute SAS programs for study data analysis and preparation for clinical study report
  • Develop specifications, build and execute SAS programs for internal data reviews, publications, exploratory, post-hoc and regulatory review
  • Develop SAS macros and tools for repeated program use for exploratory and post-hoc analyses
  • Manage on-time and quality delivery of CRO-generated analyses results
  • Review & provide feedback on CRO generated Statistical Analyses Plans and SDTM and ADaM specifications for domain and analysis dataset development, CDISC compliance and output displays
  • Validate data and results of statistical analyses generated by CROs
  • Manage internal programming resources for study deliverables as applicable
  • Stay current with regulatory requirements on CDISC and clinical regulatory programming standards
  • Utilize CDISC implementation guides and industry validation software to check compliance of CDISC data packages (SEND, SDTM, and ADaM, define.xmls and reviewer’s guides)
  • Evaluate CDISC electronic data packages for completeness, regulatory standards compliance and submission readiness as applicable
  • Participate in standards governance and developing biometric department operational processes as applicable

Skills

Key technologies and capabilities for this role

SASCDISCSDTMADaMSAS MacrosStatistical Analysis PlansClinical Trial Data Management

Questions & Answers

Common questions about this position

Is this position remote?

Yes, the position is remote.

What is the salary for this role?

This information is not specified in the job description.

What skills are required for the Associate Director, Statistical Programming role?

Required skills include experience in statistical programming, knowledge of CDISC standards and regulatory programming, familiarity with SAS programming, and understanding of clinical trial data management.

What is the company culture like at Corcept Therapeutics?

This information is not specified in the job description.

What makes a strong candidate for this position?

A strong candidate will have experience in statistical programming with SAS, knowledge of CDISC standards, regulatory programming, and clinical trial data management, as these are explicitly listed in the requirements.

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters
1998Year Founded
$39.7MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Remote Work Options
Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.
Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.
Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.
Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.
Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.
Advancements in drug delivery systems could enhance Corcept's product efficacy.
The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI